Shire submits application for FDA approval of Gaucher drug

09/1/2009 | American City Business Journals

Shire filed a new-drug application with the FDA for velaglucerase alfa, a treatment for patients with Type 1 Gaucher disease, ahead of schedule. The company expedited development of the drug amid a shortage of rival drug Cerezyme, caused by a viral contamination at Genzyme's manufacturing facility in Boston.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL